Search Results
Oct 23, 2025, 08:00 ET Ginkgo Bioworks in Partnership with STRM.BIO and University of British Columbia in Project to Develop In Vivo CAR Therapies Under ARPA-H's EMBODY Program
vivo that are safe for repeat dosing. Our vision is to open the door to the future of medicine for patients living with rare diseases worldwide and bring gene therapy to life. Please visit
More news about: Ginkgo Bioworks
Oct 23, 2025, 07:00 ET Genprex Collaborators to Present Positive Preclinical Data on the Use of Reqorsa® Gene Therapy for the Treatment of Lung Cancer at the 2025 AACR-NCI-EROTC International Conference on Molecular Targets and Cancer Therapeutics
Tumor Suppressor Candidate 2 (TUSC2) is a tumor suppressor gene that is known to have low endogenous expression in NSCLC. REQORSA Gene Therapy, referred to as quaratusugene ozeplasmid (QO) in the abstract and developed by Genprex, is a gene therapy (TUSC2 plasmid encapsulated in non-viral lipid nanoparticles)
More news about: Genprex, Inc.
Oct 23, 2025, 07:00 ET ScaleReady Announces multiple G-Rex® Grants have been awarded to leading investigators at Children's National Hospital
together to move promising cell and gene therapies from the lab to the patients who need them most. We're thankful for the support and eager to continue this important work," said Dr. Hanley. "Children's National has been a leader in pediatric cell and gene-modified cell therapies (CGT)
More news about: Bio-Techne Corporation
Oct 23, 2025, 03:40 ET Spinogenix to Present Complete Phase 2a Clinical Trial Results for SPG601, a First-in-Class Fragile X Syndrome Treatment, at AACAP Conference
Syndrome Fragile X Syndrome (FXS) is the leading inherited form of intellectual disability and a known cause of autism that results from the silencing of the Fmr1 gene. FXS is an orphan disease affecting approximately 1 in 4-5,000 men and 1 in 6-8,000 women globally. In addition to intellectual disability, FXS patients
More news about: Spinogenix
Oct 23, 2025, 00:07 ET FDA Grants Fast Track Designation for AJ201, a First-in-Class Therapy for Kenndy's Disease
SBMA, or Kennedy's disease, is a rare X-linked inherited neuromuscular disorder caused by CAG repeat expansion in the androgen receptor (AR) gene. The resulting mutant AR protein contributes to muscle and neuron degeneration through mechanisms involving cellular toxicity, oxidative stress, and
More news about: AnnJi Pharmaceutical Co., Ltd.
Oct 22, 2025, 23:30 ET MGI Tech partners with Eva Holding Group to enhance the accuracy of disease monitoring
Holding Group comprises four brands focused on different segments, all with DNA as a central tool: - Predictus Gene – focused on human predictive analysis through whole genome sequencing (WGS). - OLLIN – dedicated to the clinical
More news about: MGI TECH
Oct 22, 2025, 23:25 ET MGI Tech firma parceria com o Grupo Eva Holding para ampliar a precisão no monitoramento de doenças
Holding é composto por quatro marcas focadas em diferentes segmentos, todas tendo o DNA como ferramenta central: - Predictus Gene – voltada para análises preditivas humanas por meio de sequenciamento degenoma completo (WGS).- OLLIN – dedicada ao diagnóstico clínico
More news about: MGI TECH
Oct 22, 2025, 23:18 ET FDA Grants Fast Track Designation for AJ201, a First-in-Class Therapy for Kenndy's Disease
SBMA, or Kennedy's disease, is a rare X-linked inherited neuromuscular disorder caused by CAG repeat expansion in the androgen receptor (AR) gene. The resulting mutant AR protein contributes to muscle and neuron degeneration through mechanisms involving cellular toxicity, oxidative stress, and
More news about: AnnJi Pharmaceutical Co., Ltd.
Oct 22, 2025, 23:12 ET A DFSK comemora 20 anos de expansão global com o E5 PLUS, o primeiro novo modelo estratégico de energia no exterior, que sai da linha de produção
verde. Como um SUV de tamanho médio da marca DFSK, o novo E5 PLUS está posicionado como um "SUV Reliable Life Partner". Ele integra o gene "PLUS" em todos os detalhes do produto por meio de uma otimização precisa adaptada aos cenários diários dos usuários, redefinindo o valor de um novo
More news about: DFSK
Oct 22, 2025, 15:54 ET Ecovyst to Host Third Quarter 2025 Earnings Conference Call and Webcast on Tuesday, November 4, 2025 at 11:00 a.m. ET
https://www.ecovyst.com. Investor Contact: Gene Shiels(484) 617 [email protected]
More news about: Ecovyst Inc.
Oct 22, 2025, 11:57 ET DFSK célèbre 20 ans d'expansion mondiale avec le lancement de la ligne de production de l'E5 PLUS, le premier modèle stratégique d'énergie nouvelle à l'étranger
En tant que SUV de taille moyenne sous la marque DFSK, le tout nouveau E5 PLUS se positionne comme un "SUV partenaire de vie fiable". Il intègre le gène "PLUS" dans chaque détail du produit grâce à une optimisation précise adaptée aux scénarios quotidiens des utilisateurs, redéfinissant la valeur d'un
More news about: DFSK
Oct 22, 2025, 11:30 ET SkylineDx Publishes Landmark MERLIN_001 Trial in JAMA Surgery Validating the Predictive Power of the Merlin CP-GEP Test in Melanoma
Merlin CP-GEP (Clinico pathological-Gene Expression Profiling) Test accurately stratifies melanoma patients by sentinel node metastasis risk, showing a greater than three-fold difference between High-Risk and Low-Risk groups Largest prospective gene expression profile study in melanoma
More news about: SkylineDx
Oct 22, 2025, 10:00 ET GemPharmatech announces research collaboration with leading cancer center to advance antibody discovery
Part of the world's largest library of genetically engineered mouse models (GEMMs), the immunoglobulin gene-humanized mouse model- NeoMab®, carries the full variable gene repertoire of human heavy and kappa light chains, and regulatory elements, in a BALB/c background. This innovative design
More news about: GemPharmatech
Oct 22, 2025, 09:03 ET REPROCELL USA Receives Funding from the Maryland Stem Cell Research Fund (MSCRF)
banks. The addition of new CDMO capabilities will allow REPROCELL to provide working cell banks for cell therapy products, GMP grade differentiation, gene editing services and large-scale mesenchymal stem cells (MSC) generated from hiPSC, known as iMSC. This grant from MSCRF under their manufacturing assistance
More news about: REPROCELL USA
Oct 22, 2025, 08:30 ET The Evolution of Precision Medicine in Age-Related Neurological Diseases, Upcoming Webinar Hosted by Xtalks
endpoints, clinical trials can be more precise in measuring outcomes and evaluating emerging therapies, including advanced modalities like cell and gene therapies. A central theme of the webinar will be patient centricity. Older adults face distinct challenges in clinical trial
More news about: Xtalks
Oct 22, 2025, 05:12 ET DFSK Celebrates 20 Years of Global Expansion with E5 PLUS, the First Overseas New Energy Strategic Model, Rolls Off the Production Line
As a mid-size SUV under the DFSK brand, the all-new E5 PLUS is positioned as a "Reliable Life Partner SUV." It integrates the "PLUS" gene into every detail of the product through precise optimization tailored to users' daily scenarios, redefining the value of a new energy family SUV with
More news about: DFSK
Oct 22, 2025, 04:37 ET DFSK Celebrates 20 Years of Global Expansion with E5 PLUS, the First Overseas New Energy Strategic Model, Rolls Off the Production Line
As a mid-size SUV under the DFSK brand, the all-new E5 PLUS is positioned as a "Reliable Life Partner SUV." It integrates the "PLUS" gene into every detail of the product through precise optimization tailored to users' daily scenarios, redefining the value of a new energy family SUV with
More news about: DFSK
Oct 21, 2025, 17:31 ET Emphysema Market Analysis Reveals Promising Growth Opportunities and Trends During the Forecast Period (2025-2034) | DelveInsight
Beam Therapeutics' BEAM-302 is an investigational therapy developed by Beam Therapeutics, representing a novel gene-editing approach to the treatment of emphysema. Utilizing base-editing technology to precisely correct disease-causing mutations, BEAM-302 aims to restore
More news about: DelveInsight Business Research, LLP
Oct 21, 2025, 15:31 ET Dr. Juan Fortea discusses his groundbreaking research redefining APOE4 homozygosity as a genetic cause of Alzheimer's and his upcoming webinar
perspective on the future of Alzheimer's clinical research and disease treatment – especially for APOE4 homozygotes (people with two copies of the APOE4 gene, widely considered the strongest genetic risk factor for late-onset Alzheimer's disease). Fortea's career in behavioral neurology
More news about: ApoE4 Alzheimer's Alliance
Oct 21, 2025, 14:33 ET Researchers Link Orphan Gene in SARS-CoV-2 Virus to More Severe Cases of COVID-19
infections, hospitalizations and deaths – the researchers found that less than 5% of genomes carried any mutations of the ORF10 orphan gene, meaning that the gene was mostly preserved as the virus evolved and continued to infect humans. In fact, four ORF10 mutations were associated with less
More news about: Children's Hospital of Philadelphia
Oct 21, 2025, 14:33 ET Children's Hospital of Philadelphia Researchers Identify Distinct Pro-Inflammatory Epithelial Cell State in Crohn's Disease Patients
cells from a patient's colon. Single-cell transcriptomic and epigenomic approaches were used on matching tissue specimens to investigate epithelial gene expression and function in healthy children and adults compared with patients with Crohn's disease. The study identified an inflammatory
More news about: Children's Hospital of Philadelphia
Oct 21, 2025, 11:50 ET Pioneering Physician-Scientist Dr. Francis S. Collins Joins ImmunoBrain Board of Directors
an active research group at the University of Michigan and the NIH for 41 years, doing groundbreaking research on type 2 diabetes and discovering the gene misspellings that cause cystic fibrosis, Huntington's disease, progeria, and several other disorders. A former director of the National Human Genome
More news about: ImmunoBrain Checkpoint Inc.
Oct 21, 2025, 09:39 ET Alcami to Expand Laboratory Services Footprint at Durham, NC Facility to Meet Growing Demand in Biologics
significantly strengthen Alcami's analytical capabilities in support of biologics, peptides, oligonucleotides, antibody-drug conjugates (ADCs), and cell and gene therapy (CGT) drug substances and drug products. The Creekstone Drive site will feature expanded capacity for method establishment, release and stability
More news about: Alcami
Oct 21, 2025, 09:20 ET Beyond Traditional Drugs: Novel Platforms Targeting Hard-to-Treat Conditions
growth to $463.11 billion by 2034[2], driven by breakthroughs in gene editing technologies and personalized therapeutic approaches that match treatments to individual genetic profiles. October 2025 saw multiple gene therapies receive platform technology designations and rare disease pathway
More news about: Equity Insider
Oct 21, 2025, 08:30 ET Immusoft Receives FDA Fast Track Designation for ISP-001, a First-in-Class Engineered B Cell Therapy for MPS I
be treated, one that offers the potential for long-term, continuous therapeutic protein delivery that avoids many of the limitations of traditional gene therapy approaches." Fast Track is a process designed to facilitate the development and expedite the review of new drugs and
More news about: Roberts Communications